secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2026-06-18T11:12:58+00:00
Accession:  0001193125-26-274950
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta advances zelicapavir to registrational Phase 2b/3 trial in high-risk adults with RSV; pediatric Phase 2b planned
--------------------------------------------------------------------------------

- Registrational Phase 2b/3 trial in high-risk adults (≥75 yrs, COPD, CHF) to start 4Q 2026; Phase 2b topline data expected 2027.
- Phase 2b pediatric trial (28 days-36 months) to start 3Q 2026; topline data expected 2027; conducted with Penta Foundation and Chiang Mai University.
- FDA End-of-Phase 2 meeting successful; trial design includes 800mg oral zelicapavir once daily for 7 days vs placebo.
- Enanta estimates global market opportunity for oral RSV antiviral >$2B; US addressable population >3M patients.
- No available treatment options for RSV; zelicapavir could be first antiviral therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000119312526274950/0001193125-26-274950-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000119312526274950/d159604d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-274950

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer